Month: August 2025

Categories
Health

Eli Lilly Odipositas Pille Orforlipron led to a weight lack of 12%

Eli Lilly Odipositas Pille Orforlipron led to a weight loss of 12%

Eli Lilly On Thursday, the highest dose of his daily obesity pill gave the patient to lose almost 12% of their body weight or about £ 27 in a late study in order to pave the way for entry into the market.

The weight loss of the pill was 11.2% in the analysis of all patients, regardless of the interruption.

The company's shares decreased by 13% on Thursday. Meanwhile shares of the rival Novo NordiskWhat also works on bringing an obesity pill onto the market rose by more than 7%on Thursday.

The data comes under the analysts of Wall Street for Eli Lillys Oraler GLP-1 with the hope of weight loss of around 15%. Some doctors said the results seem to be comparable, but overall a little lower, which is the weight loss with the weight loss observed Novo Nordisk'S blockbuster Weekly GLP-1 injection for obesity, Wegovy.

Some doctors also noticed the number of patients with the highest dose of the pill, which set up treatment due to side effects or other reasons in the study.

Nevertheless, other doctors praised the results and the potential of the pill to achieve new patients, such as those who are afraid of needles.

“This is a strong and promising result for an oral agent,” said Dr. Jaime Almandoz, medical director of the weight -wellness program at UT Southwestern Medical Center and described the weight loss “an important and clinically meaningful result”.

“Injicable have set a high bar, but this study increases the potential that an oral GLP-1 is transformative in obesity treatment, especially in patients who hesitate to start or maintain injectable therapies,” he continued.

Dr. Mihail “Misha” Zilbermint, director of the doctors of the Johns Hopkins Community, said he thinks that the pill “has the potential to be a player as long as people can tolerate the side effects”.

The study results are among the most observed studies of the year of the pharmaceutical industry and follow positive data in April from a phase -three study in which the experimental pill was examined in diabetes patients. They bring Eli Lillys Pill, Orforlipron, a step closer to potentially become a new, needle-free alternative without the dietary restrictions on the booming market for weight loss and diabetes medication, which are called GLP-1.

Eli Lilly is “not disappointed with these results. It is correct for us, even though she” “one or two points under what the street had,” CEO David Ricks told CNBCs “Squawk Box” on Thursday.

“The goal was to create an oral pill that was comfortable and can be made on a large scale for the mass market at a large level and had weight loss that was competitive with other single-effects GLP-1, and we have achieved that,” said Ricks. He added that the percentage of weight loss of the pill “in the area” of what most people want to achieve who are overweight or want to improve their health health.

Ricks said that Eli Lilly expected to submit the data to the supervisory authorities by the end of the year with the hope of starting the pill “this time next year” around the world.

This start could fundamentally change the space, more patients help access to the treatments and the relief of the supply failures of existing injections. The more convenient and lighter pill could also help Eli Lilly to consolidate his dominance in the growing segment, since other drug manufacturers, including the most important competitor Novo Nordisk, bring weight pills onto the market.

There are approximately 8 million patients with injectable obesity and diabetes medication, but probably around 170 million who could benefit from the medication, said Ken Custer, President of the Lilly Cardiometabolic Health.

“In order to satisfy this demand, we need other options, including oral small molecules such as Orforlipron, which use different means of production and do not need a demanding supply chain to distribute them to patients,” he said.

Dr. Amy Sheer, professor of medicine and program director of the specialist dealer Medicine Fellowship at the University of Florida, hopes that the pill will be cheaper than existing injections that are primarily due to the devices. You could contribute to this.

Many insurers still do not cover GLP-1 for obesity. WEGOVY and other medication have list prices of around $ 1,000 in front of the insurance company.

Detailed test results

The highest dose Eli Lillys Pille helped more than 59% of the patients to lose at least 10% of their body weight, and more than 39% of the patients lose at least 15% of their weight.

Almandoz said the proportion of people who have achieved “larger sizes” of weight loss

Orforlipron also helped reduce cardiovascular risk factors.

Data about how well some patients tolerated the pill in the study were folded under the estimates of the analysts.

About 10.3% of the patients who had the highest dose of the pill – 36 milligrams – deployed the treatment due to side effects, compared to around 2.6% of those who earned a placebo. These side effects were mainly gastrointestinal, such as nausea and vomiting and moderately to moderate. An estimated 24% of those who took the highest dose experienced vomiting, while 33.7% or 23.1% had nausea or diarrhea.

Before the data, the BMO Capital Markets Analyst Evan Seogerman said that it expected less than 10% of patients with the highest dose of the pill to cancel the treatment due to side effects and lower inheritance rates, nausea and diarrhea.

Other patients no longer have the pill on the market due to side effects compared to existing GLP-1, said Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness in the Brigham and Women's Hospital. The dismissal rates due to side effects in studies in the late stage for path effects and Eli Lilly's weekly obese injection injection zepbound are around 7% or less.

More CNBC health insurance

She found that almost a quarter of the patients with the highest dose of the pill broke off treatment for some reason, since the enthusiasm for Orforlipronem should be reduced “because we get all this excitement and then get out the pill, and then nobody can take it.”

It is unclear why these patients have broken off the pill apart from side effects. Almost 30% of those who were treated on a placebo treatment for some reason.

Eli Lillys Ricks said the company was not concerned about these dropout rates in the study.

“What we really want to see is that the medication breakdown is lower than placebo, and we saw that here,” he said, referring to the demolition rates for some reason.

Ricks added that Eli Lilly was looking for a dropout rate of less than 12% due to side effects, and found that the industry recorded 8% to 12% with GLP-1 medication.

“We are right in the middle,” he said. “The continuation rates in this category are not perfect in all categories of chronic medicines. However, the failure of the drug, and here we are back with the profile.”

The Sheer of the Florida University said that she does not believe that the discontinuation or side effects will be a decisive factor for doctors if you prescribe the pill.

She believes that an oral option could actually make more doctors more comfortable to prescribe patients an GLP-1. Some doctors are currently hesitation to prescribe injections because they “may not know how to tell the patients how they should use them,” added Sheer.

According to Almandoz, prescription decisions depend on the specific needs and preferences of the patient as well as access and affordability. An injectable GLP-1 can be the preferred option for patients whose priority has a higher level of weight loss or those with considerable cardiometabolic complications or health problems from cardiovascular diseases and metabolic disorders.

However, an oral GLP-1 could be suitable for those who “prioritize simplicity or convenience or have these logistical challenges with injections,” he said.

The detailed results of the experiment will be presented at a European medical meeting in September and published in a journal examined by experts. Further study results of phase three in the pill will be shared later this year, including a study of adults with obesity or overweight and type -2 diabetes.

Wegovy, Eli Lillys Pille, Oroflipron and Novo Nordisks Diabetes Pill Rybelsus all work by targeting an intestinal hormone called GLP-1 to promote weight loss and regulate blood sugar. But in contrast to these other medication, Eli Lillys Pille is not a peptide medication. This means that it is more easily absorbed in the body and does not require dietary restrictions such as Rybelsus.

Eli Lilly is currently about three years in front of other drug makers who develop pills, including Pfizer, Astrazeneca, Roche, Struction Therapeutics and Viking Therapeutics, Guggenheim Analyst Seamus Fernandez before CNBC.

Some analysts expect the GLP-1 market to be worth more than $ 150 billion annually in the early 2030s. According to Fernandez, oral GLP-1 could grow at a value of $ 50 billion of this total total.

– Angelica Peebles from CNBC contributed to this report.

Do not miss these findings from CNBC Pro

Categories
Science

Trump Administration brings purpose to the emission database of the EPA – Watts?

Trump Administration brings reason to the emission database of the EPA - Watts?

Charles Rotter

The decision of the environmental protection authority to update the database “Supply-TreeHouse-Gas emission factors” marks a turning point from the ritualized burden of “climate skills” of companies in the direction of an optimized, reality-based approach to government. Under the Trump Administration, this shift reflects an overdue out of priorities – apart from the endless accounting of speculative environmental sins and the concentration on the core mission of the agency, health and the environment with proven, relevant science.

Of course, the New York Times dealt with the decision as if it were the collapse of civilization itself. The tone of its reporting was a pure caterwauling – an “important setback for corporate climate action” and the supposed loss of one of the most important data records to estimate the value creation emissions about the supposed loss of “one of the most important data records”. The readers were almost able to hear the background when the paper mourned around the emergency of the companies, which had now withdrawn a moral scorecard cultivated by the EPA for their supply chains.

The utility model developed by Wesley Gingersen was essentially a denominational carbon stand for companies. Companies could enter their expenses for wood, metal, shipping or other supply chain components and receive an estimate- lungs with assumptions- their greenhouse gass “footprint”. This exercise was not voluntary for many; The regulations of the European Union and the mandate for 2027, which was upcoming in California, ensured that companies were playing together or being exposed to punishments. In practice, this meant that companies were put under pressure to make costly changes in the company, not on the basis of concrete, measurable damage, but because a statistical model said this.

The popularity of the model was undeniable-was classified as the third best data record on Data.gov. However, popularity is not proof of accuracy or necessity. Like a bestseller diet, the Useeo system has addressed because it promised a proper way to quantify virtue -or the lack of it. The problem is that the climate calculation of this kind is intensified with uncertainties. For example, it is assumed that entire supply chains in the United States completely exist and the reality ignores that many goods from countries are imported with very different production profiles. This means that the issue is at best an approximation and, in the worst case, a misleading guide for costly guidelines and business decisions.

In a larger context, the system was also fed directly into a global investment machinery that grew around the “climate crisis” story. Partnerships such as the 2007 between Al Gore's Generation Investment Management and Silicon Valley Venture Capital Giant Kleiner Perkins Caufield & Byers were expressly developed to hand over capital to companies in order to benefit from regulations, subsidies and market shifts that were created according to climate policy. Their common focus included renewable energies, the structure of efficiency, “cleaner” fossil energy, sustainable agriculture and carbon markets – all sectors that benefit from the type of compliance that the useio database has retained during enforcement.

The Times framed the departure of Dr. Ingwersen – after signing a politically accused letter in which the administration of the EPA mission was signed – as a martyrdom of a noble scientist. But the EPA made it clear that it will not tolerate career agencies in order to undermine, undermine, sabotage, sabotage and undermine the will of the American public. “

Critics such as the former EPA official Paul Anastas warn that the shift in research to the private sector could reduce credibility. In this case, a private consortium that has already committed the university companies and environmental analysis companies in Stanford and the company analysis company – to maintain and even improve the data record, which means that it remains free for the public. This agreement underlines the point: If a project has a real value, private actors will maintain it without forcing the taxpayers to take the invoice for an indefinite period.

By eliminating the constant deviation of updates in a speculative emission database, the administration has reduced a layer of bureaucratic fat that camouflaged as a moral necessity. The companies that really want this data – either for public relations or to meet foreign regulatory requirements – can still access them that are now financed by those that they consider indispensable. For the rest, it is a less mandatory climate skill and a further memory of the fact that federal authorities are not able to enforce trust in models, but to protect public interest with solid, verifiable science.

If at all, this step should be regarded as an example of the governance of governance, the compulsion to get involved in the number of uncertainty, remove the type of NYT melodrama that fills a data management decision for an attack on civilization, and the seamless conversion of the taxpayer with the foundation of “climate data” into private investment opportunities. The private sector can do virtue signal exercises for those you want. Meanwhile, Washington has more urgent and material environmental problems.

Like this:

How Load…

Do you discover more from watts?

Subscribe to the latest posts to your e -mail.

Categories
Technology

Stammzellen -Startup proklamiert den „Flexionspunkt“ für die Medizin, wenn sich die Massenproduktion nähert

Stammzellen -Startup proklamiert den „Flexionspunkt“ für die Medizin, wenn sich die Massenproduktion nähert

Es ist Erntetag am Karolinska Institute in Stockholm. Als Sunshine den Campus der Gutey University badet, arbeiten Wissenschaftler in den Labors unter kühlem fluoreszierendem Licht. In grüner Schutzausrüstung gekleidet und neigen akribisch dazu, Röhrchen in hermetisch versiegelten Reinräumen zu testen. Die Behälter halten die Früchte der heutigen Arbeit: mesenchymale Stammzellen (MSCs).

Jede Zelle ist kaum ein Viertel der Breite eines menschlichen Haares, führt jedoch eine bemerkenswerte Kraft aus. MSCs reduzieren Entzündungen, reparieren beschädigtes Gewebe und modulieren das Immunsystem. Sie können chronische Krankheiten behandeln und das Altern verzögern. Sie können sogar Krankheiten verhindern, bevor sie beginnt. Um jedoch eine Hauptstütze der modernen Gesundheitsversorgung zu werden, müssen MSCs erschwinglich und zuverlässig im Maßstab produziert werden.

Das schien bis vor kurzem eine entfernte Aussicht zu sein, aber die Karolinska -Wissenschaftler glauben, dass es sich der Realität nähert. Sie arbeiten für CellColabs, ein schwedisches Startup, das sich gebildet hat, um die globale Knappheit von Stammzellbehandlungen anzugehen.

CellColabs glaubt, dass dieser Mangel bald überwunden werden könnte. Dank einer Mischung aus wissenschaftlichen, regulatorischen und technologischen Fortschritten kunden MSCs auf den Verbrauchermarkt aus. Innerhalb des nächsten Jahrzehnts zielt CellColabs darauf ab, die Preise um bis zu 90%zu senken.

Die 💜 der EU -Technologie

Die neuesten Gerüchte aus der EU -Tech -Szene, eine Geschichte unseres weisen alten Gründers Boris und einige fragwürdige KI -Kunst. Es ist jede Woche kostenlos in Ihrem Posteingang. Melden Sie sich jetzt an!

Im Labor sieht der Fortschritt beeindruckend aus. Die jüngste Ernte, die aus einer einzigen Spende kultiviert wurde, hat 4,1 Milliarden Zellen für bis zu 200 Standarddosen ausreichend.

Der CEO von CellColabs, Dr. Mattias Bernow, ist in einer lebhaften Stimmung. Der 43-Jährige sieht den heutigen Anbau nur einen Vorgeschmack auf das, was kommen wird.

“Ich glaube wirklich, dass wir uns an einem Wendepunkt in der Geschichte der Medizin befinden”, sagt er.

Die Kraft von MSCs

MSCs existieren natürlich im Körper. Ein typischer Mensch enthält Milliarden davon. Sie verhalten sich wie eine Reparaturmannschaft und reparieren und stimmen unsere Innenseiten ein. Sie können auch extrahiert, multipliziert und in medizinische Behandlungen verwandelt werden.

Karolinska war der Ort eines der größten Meilensteine des Feldes. 2012 verlieh seine Nobelversammlung John Gurdon und Shinya Yamanaka den Nobelpreis für Physiologie oder Medizin. Sie entdeckten, dass reife Zellen pluripotent gemacht werden können – in der Lage, fast jeder Zelltyp im Körper zu werden. Der Durchbruch hat die Regeln der regenerativen Medizin neu geschrieben, wodurch frische regulatorische Impuls und schnelle Stammzelltherapien zündeten.

MSCs gehören zu den vielversprechendsten Beispielen. Wenn sie injiziert werden, geben sie Signale frei, die Heilung auslösen. Der Körper repariert sich dann.

Sie können unzählige Erkrankungen behandeln, von Arthritis und Herzerkrankungen bis hin zu Immunstörungen. Aber zuerst müssen Sie eine kleine Probe aus einem lebendigen, atmenden Menschen extrahieren.

CellColabs bezieht seine MSCs aus dem Knochenmark gesunder Spender im Alter von 18 bis 30 Jahren. Nur 50 Milliliter – über ein Schnapsglas – produziert bis zu 200 Dosen. Das Mark regeneriert sich natürlich in sechs bis acht Wochen.

Der Spendenprozess ist schnell und minimal invasiv, aber die Massenproduktion ist notorisch herausfordernd. MSCs sind lebende Zellen, die eine komplexe Bioperation, sorgfältige Handhabung und strenge Qualitätskontrolle erfordern, was die Skalierung zu einer gewaltigen Aufgabe macht.

CellColabs sieht dennoch die Produktion in der Industrie im Horizont-vor allem der Pionierforschung von Professor Katarina Le Blanc.

Die wegweisenden Arbeiten von Le Blanc zeigten, dass MSCs entzündliche und Immunkrankheiten bekämpfen konnten. Ihre Ergebnisse zeigten auch, dass gespendete Zellen für den therapeutischen Gebrauch geeignet waren – ein entscheidender Schritt für die Kommerzialisierung.

Sie half bei der Erstellung von Produktionsstandards in klinischer Qualität und ebnete den Weg für groß angelegte Studien und den breiteren therapeutischen Gebrauch. Ihre Forschungen legten die Grundlagen für Bernows Wendepunkt.

“Dies ist keine Gehirnoperation oder Raketenwissenschaft, aber es sind Stammzellen – also ist es ziemlich nah”, sagt er. “Es ist super komplex. Und der einzige Grund, warum wir dies tun und uns so schnell bewegen können, ist die Forschung von Professor Le Blanc.”

Als Hämatologe untersuchte Le Blanc das Potenzial von MSCs zur Unterstützung von Blutkrebspatienten. Ihre frühe klinische Arbeit konzentrierte sich auf die Erkrankung der Transplantat-gegen-Wirt-Erkrankung-eine schwere und oft tödliche Komplikation von Knochenmarktransplantationen. In einer kleinen Studie verabreichte ihr Team Patienten, die nicht auf Standardtherapien reagiert hatten, MSCs. Der Einfluss war auffällig: Mehr als die Hälfte der Teilnehmer überlebte. “Das gesamte Feld hat nur in die Luft gesprengt”, sagt Bernow.

Le Blanc drückte weiter in Neuland. Ein Versuch reparierte Stimmfalten und restaurierte die Sprache mit minimaler Narben. Eine andere Studie verwendete MSCs bei COVID-19-Patienten, um Entzündungen zu verringern. Die Ergebnisse waren vielversprechend – aber sie traf eine Mauer. “Sie hat die Zellen ausgelöst”, sagt Bernow.

Skalierung wurde zu einem neuen Fokus. Um den Zugang zur Behandlung zu erweitern, um den Zugang zu den Behandlungen zu erweitern, spendete Le Blanc 2021 ihre Forschung an CellColabs. Zwei Jahre später erhielt die Karolinska -Einrichtung die Genehmigung der Produktion.

Die Produktionskosten sind seitdem rasant gesunken und die Hoffnungen auf eine zehnfache Reduzierung. Wenn die Preise sinken und die Ausgangsskalen senken, hat Bernow seine Augen auf ein Ziel: „Der Zugang zu Stammzellen zu demokratisieren.“

Mattias BernowNach Zauber als ER -Arzt, Beraterin und Startup -Gründerin, Mattias Bernow, schloss sich 2021 Zellcolabs an. Credit: CellColabsMattias Bernow

Eine neue Welt der Behandlungen

Zurück im Labor führt CPO Lina Sörvik eine Tour durch die Einrichtungen. Zuvor war sie eine ältere Figur in Big Pharma und trat CellColabs bei, nachdem sie vom Potenzial von MSCs fasziniert war.

„Ich ließ mich von dem inspirieren, was sie tun konnten, und von der Idee, eine Einrichtung zu erstellen, um sie zu produzieren“, sagt sie.

An einem Erntetag beginnt die Arbeit ihres Teams um 7:00 Uhr. Wissenschaftler ziehen die volle Schutzausrüstung an und verbringen den Tag damit, in den Karolinska -Reinräumen zu arbeiten. Sobald sie die MSCs geerntet haben, werden die Zellen auf Qualität getestet und für zukünftige Verwendung eingefroren.

Der Bereich ihrer Anwendungen ist umfangreich. Patienten mittleren Alters können sich von Gelenkschmerzen und Verletzungen lindern. Sportler können ihre Erholung von Verletzungen beschleunigen. Ältere Menschen konnten ihre Alterung verlangsamen.

Brian Johnson, ein Tech -Unternehmer und Promi -Anwalt für Langlebigkeit, hat ebenfalls ihre Kräfte untersucht. Er ließ 300 Millionen MSCs von CellColabs produziert, die in die Knie, Schultern und Hüften injiziert wurden.

Bernow lobt die Vielfalt der Behandlungen. Er sagt, dass MSCs “für fast jeden Hinweis” interessant sind.

Sein Weg zu ihnen war kurvenreich. Bernow wurde in Malmö im Südwesten Schwedens aufgewachsen und zog in die Hauptstadt des Landes, um an der Stockholm School of Economics (SSE) zu studieren.

“Zu dieser Zeit wollte jeder in London Banker werden”, erinnert er sich. “Das war nicht die Zukunft, die ich für mich selbst gesehen habe.”

Er erweiterte sein Studium und machte einen medizinischen Abschluss am Karolinska Institute und einen MSC von SSE. Nachdem er als klinischer Arzt und Verwaltungsberater gearbeitet hatte, war er Mitbegründer von Doctrin, einer digitalen Gesundheitsplattform. Dann rief CellColabs an: Das Führungsteam brauchte einen CEO und sah Bernow als perfekte Passform.

“Ich wusste, dass es mehr Blut, Schweiß und Tränen sein würde”, sagt er. “Aber je mehr ich las, desto faszinierter wurde ich.”

Was ihn am meisten faszinierte, war das Potenzial von MSCs, chronische Erkrankungen zu behandeln – die häufigste Todesursache der Welt. “Deshalb denke ich, dass wir wirklich an einem Wendepunkt in der Geschichte der Medizin sind.”

Die neuen Antibiotika?

Bernow teilt gerne ein Zitat von Joseph Martin, dem ehemaligen Dekan der Harvard Medical School: “Stammzelltherapien haben das Potenzial für chronische Krankheiten, was Antibiotika für Infektionskrankheiten getan haben.”

Es ist ein mutiger Vergleich. Bevor Alexander Fleming 1928 Penicillin entdeckte, könnten kleinere Infektionen tödlich sein. Gesunde Menschen starben jung oder schnell gealtert.

Ein Jahrhundert später ließen uns Antibiotika länger leben, ein besseres Leben. Infektionskrankheiten sind nicht mehr die Hauptursachen für Todesursachen. Sie wurden durch chronische Erkrankungen wie Herzerkrankungen, Schlaganfall, Alzheimer, Parkinson und Diabetes ersetzt. Wir leben jetzt auch mit altersbedingten Krankheiten, die die Lebensqualität stark verringern.

Laut Bernow kann MSCs dazu beitragen, die wachsende Belastung durch chronische Krankheiten zu lindern. “Aber als Arzt finde ich am interessantesten das Potenzial, den Auftreten von Krankheiten zu verhindern oder zumindest zu verzögern.”

Er erinnert sich an seine Zeit in der Notaufnahme und behandelte Herzpatienten. Ein typischer Fall war ein Mann mittleren Alters, der gerade sein erstes Herzereignis erlitten hatte, das jetzt zu einer geringeren Qualität und möglicherweise kürzer war. MSCs hätten dieses Ergebnis verändern können.

Ihre regenerativen und entzündungshemmenden Kräfte könnten die Genesung unterstützen-oder sogar das Ereignis insgesamt verhindern.

Um dieses Potenzial zu erreichen, zielt CellColabs auf einen neuen Launchpad für Skala: Bioreaktoren.

Skalierung für die Zukunft

In den Karolinska -Reinräumen wächst CellColabs derzeit MSCs auf flachen Oberflächen im Zellmedium. Bioreaktoren bieten ein vielversprechendes Upgrade.

Indem sie stark wachsende Kultivierungsoberflächen und automatisierte, streng kontrollierte Wachstumsbedingungen ermöglichen, könnten sie die Produktion weit über das, was mit den heutigen Methoden möglich ist, überschreiten.

Wissenschaftler im Zellcolabs ReinraumBioreaktoren können viele der derzeit in den Reinräumen verwendeten manuellen Methoden ersetzen. Kredit: CellColabsWissenschaftler im Zellcolabs Reinraum

CellColabs entwickelt seine Bioreaktorplattform mit dem Royal Institute of Technology in Stockholm. Bernow erwartet, dass es die Produktion transformiert und die MSC -Ausgabe um ein Vielfaches vervielfacht.

Der vollständige Start ist für 2028 geplant. Bis dahin hofft CellColabs auch über überzeugende neue Beweise für die Vorteile von MSCs.

Das Startup ist derzeit an vielversprechenden Tests auf den Bahamas und Abu Dhabi beteiligt. Beide Standorte haben progressive, patientenfreundliche und ethisch regulierte Rahmenbedingungen für MSC-Studien erstellt, die sie in der Branche zurückgelegt haben.

An ihren Teststellen untersuchen Wissenschaftler Behandlungen für eine Vielzahl von Erkrankungen: Verletzungen des Bewegungsapparates, Knieosteoarthritis, kardiovaskuläres Risiko, Arthritis und altersbedingte Gebrechlichkeit.

In kleineren Territorien wie diesen ist es einfacher, die medizinischen Vorschriften für aufstrebende Therapien zu aktualisieren. Wenn sie erfolgreich sind, erwartet Bernow, dass andere Nationen ihrer Führung folgen und ihre Unterstützung für MSCs beschleunigen. Die potenziellen Vorteile, so argumentiert er, sind enorm.

Er stellt sich vor, dass die winzigen Zellen die Gesundheitssysteme von reaktiv auf vorbeugendem reagieren und die Kosten senken und gleichzeitig chronische Erkrankungen in Angriff nehmen können. Unser Leben würde nicht nur länger wachsen – sie wären gesünder und glücklicher.

Bernow stellt einen Kontrast zu den jüngsten Fortschritten in der westlichen Medizin. Wir leben länger, aber unsere späteren Jahre werden oft durch Gebrechlichkeit, Krankheit und ein begrenzter Existenz beeinträchtigt.

“Wir haben Jahre mit der Qualität der niedrigeren Lebensqualität hinzugefügt”, sagt er. “Wenn Stammzellen chronische Erkrankungen auftreten können, können wir unsere gesunde Lebensdauer verlängern.”

Das heißt nicht, dass MSCs einen Jugendbrunnen schaffen. Sie werden unser Leben nicht für immer erweitern, aber sie verbessern die Zeit, die wir haben, dramatisch.

“Ich möchte die ersten 100 Jahre damit verbringen, hoch aktiv und mit meiner Familie zu sein – mit meinen Kindern, meinen Enkelkindern und vielleicht sogar meinen Urenkel -Enkelkindern.”

Categories
Entertainment

Frances Anderson, Reese Witherspoon & Extra Stars' Proper Title revealed

Frances Anderson, Reese Witherspoon & More Stars' Right Name revealed

What is in a name change?

For almost a decade Aubrey Anderson-emons The screens like the wise Lily Tucker Pritchett sent to modern family. However, when the 18-year-old begins her journey as a musician, she makes this with a new nickname: Frances Anderson.

“Frances is actually part of my right name – it is my second first name and it is after my mother's old friend,” she said recently to E! News before the release of your EP drown on August 8th. “I thought it was a bit shorter than Aubrey Anderson-emons. I had a long, educated last name.”

But that was not the only motivator for the name change. “I wanted to switch it on and I wanted people to see a new side from me,” continued Frances. “I wanted to create a room, especially for music. And I am very happy that everyone hears the songs on the EP, and I'm so grateful.”

Of course, the teenager is far from requesting a different name with a different name.

Categories
Science

JWST follows particulars of the complicated planetary fog

NASA’s James Webb Space Telescope’s view of NGC 6072 shows a complex scene of multiple outflows expanding at different angles from a dying star. Credit: NASA/ESA/CSA/STScI

When low mass stars approach the end of their main source phase, they sell gas clouds that expand to planetary fogs. Since they were identified for the first time at the end of the 1700s, astronomers have identified fog of all forms and sizes, with most of the circular, elliptical or bipolar. Some fogs of this pattern, including the NGC 6072 nebulae, which was about 3,060 light years in the southern constellation scorpius. In a new series of high -resolution pictures of the James Webb Space Telescope (JWST), astronomers have found some special patterns that could offer insights into the life cycle of stars.

At first glance, the pictures, which were recorded with the near infrared camera (Nicam) and the mid-infrared instrument (Miri) from WebB, indicate that NGC 6072 is a huge chaos that reminds of a beetle sprayed on a windshield. However, the structure, which is due to the instruments of WebB, suggests that some very complex mechanisms work in it. The nircam data show a hot central core area, which lights up with a light blue shade that is surrounded by elliptical drains that give it a multipolar configuration. These drains have led to two gas and dust flaps, which cross the center in almost vertical angles, while a third-party extends perpendicular to the formation of an equatorial level.

The central region covers a large area of dark pockets, which is surrounded by orange material that grows reddish, the further it is from the center. This is in line with the colder gas and dust the further it dares from the hot central core. The three-louse structure could mean that at least two stars are in the center of the fog and probably consist of a younger companion of the aging star, which has already lost most of its material. The Miri data now record the longer-wave infrared data that highlight the web-like structure that is generated by the dust outfits.

The NGC 6072 fog, as the Miri instrument from Webb mapped. Credit: NASA/ESA/CSA/STSCI

This picture also shows the star that could be of central importance for the fog (which appears as a pink-white point) and concentric rings that expand from the central region to the edges of the rags. This could also be proof of a secondary star in the center, which circles the older star and cut out rings. Alternatively, the rings could have been caused by pulsations in the drains, in which gas and dust were expelled in long intervals (every thousand years or so) in all directions. The areas that are shown by Nircam (red) and Miri (blue) both pursue the cool gas in the cloud (probably molecular hydrogen), while the central regions track hot ionized gas.

While the aging star cools down in the middle, the fog is dissolved into the interstellar medium (ISM) and contributes to the heavier elements from which new stars and planetary systems will form. Investigation of the planetary fog is a main goal for the JWST, which provides new insights into the life cycle of stars and its effects on the surrounding environments. These studies could also illuminate light on what can become of our sun if it reaches the end of its main phase in billions of years.

Further reading: Webb Space Telescope

Categories
Sport

2025 Fantasy Soccer Draft Information – rating lists, false designs and evaluation

2025 Fantasy Football Draft Guide - ranking lists, false designs and analysis

This page is updated all summer. So continue looking for the latest content.

While the weather is heating, our excitement is also over the season of the fantasy football from 2025.

Regardless of whether you play in an informal new system, an intensive format of deep dynasty or something in between, we are at ESPN Fantasy here to help.

This design leader serves as a one-stop shop for all our best material, as they prepare to make the best fantasy football picks possible in every design: ranking lists and cheat sheets; Player projections; Fein designs for different league types; Sleepers, busts and outbreaks; And a lot of helpful information and tips from our team of experts from Fantasy football analysts.

It doesn't matter whether you have been doing this for years or are a fantasy first-timer. We have everything to help you create a great team and start the season with a shot at a championship.

Fantasy Football Cheat Sheets, projections and deep cards

Your league, your rules

Create a league and adjust the league size, the rating and the rules to play in the league in which you want to play.

Create a league today!

Cheat Sheet Central
A one-stop shop for printable cheat sheets that meet your specific requirements.

2025 projections
Mike Clays projected edition for players in every fantasy position, sortable by category.

Deep cards: criminal offense | defense

Ranking

2025 ranking hub
A number of ranking types that correspond to you, including our personnel consensus according to position, superflex, IDP, dynasty and individual lists.

Mike Clays “The 192”
The 192 players who were to be collected in 12-team leagues disassembled into stages.

Insurance RB ranking
A list of backup running backs that are best positioned to be successful if you get a complete workload.

RB ranks: the most reliable TD goal scorer
Which back can you banks near the goal line? Here are the most reliable backs.

From Chase to London, which rank the most reliable TD goal shooters under WRS
A deep immersion in trustworthy TD goal shooters under Wideouts based on target data, efficiency and much more.

Schmen designs

The Mock design project 2025: Results for over 30 experts 10-team PPR mock designs

More mocks: 12-team superflex, PPR (8/5) | 10-team superflex, 1/2 PPR (7/24)
8 team, PPR (7/9) | 12 team, non-PPR (6/24)
12 team, 1/2 PPR (6/12) | 10 team, PPR (5/6)

Advice and analysis

List “Do Draft”: Henry, Purdy, Kelce among the undervalued players
In the multi -year counterpart to the list of the Do No Draft list, Eric Karabell discusses players who are underestimated in designs.

“Don't” remove “list”: McCaffrey, Andrews among the players who are overrated
Eric Karabell serves his annual list of players who were to go designs in the past than 2025.

Fantasy Football 'Drumbeat' Player: Nothing, Hampton Under them create buzz
Liz Loza serves six potential players who create serious excitement in fantasy circles.

Benson, Higgins lead the team “Have skills, need opportunities”
Ten players who have the skills to be fantasy factors, but are waiting for a chance to prove this.

Six “planes” that can help them win their league
Liz Loza offers six players who have to consider late in fantasy designs.

Fantasy Focus Breakouts: Williams, McCarthy and more
Field Yates, Mike Clay and Daniel Dopp identify players that they can count on to break out.

Numbers you should know before your draft
Tristan H. Cockcroft reveals some interesting statistics that could affect the draft of daily decisions.

Ward, McMillan and others are prepared to follow the path of 2024 outbreaks
These players are able to follow a way similar to the outbreaks of the past year and to create large numbers.

Players 2 players Spotlight: Maye, Harrison, Odunze among the popular outbreaks
The ESPN Fantasy list lists the NFL students who are undervalued in designs and are under control.

Murray, McCaffrey under “Red Fahnen” boards that are worth writing
You have to take risks to win in fantasy football. Liz Loza emphasizes players who are worth taking the chance.

Opportunity strokes: Players ready to benefit in 2025
Eric Moody lists those who benefit most from the free touch or destinations of the teams last season.

11 players who will achieve fewer TDs in 2025
Mike Clay gives his annual list of players, from whom he expects to reach the end zone less frequently this season.

Nine players who will achieve more TDS in 2025
Mike Clay lists the players who are most likely to increase their touchdown edition in 2025.

Expect a return from these bounce back candidates for the form
Eric Karabell lists some of his favorite candidates from a disappointing 2024.

10 undervalued passports with fascinating upward trend or safer soils
Matt Bowen lists his favorites with weekly potential and others who are reliable despite lower ADPS.

TOP -NOTURE STARIES FOR 2025: What you can expect from CMC, Tyreek and more
Mike Clay, Daniel Dopp and Field Yates enjoy a robust conversation about topics that fascinate them this season.

Don't be surprised if … these 19 things happen in 2025
Eric Karabell offers his thoughts on players who could enjoy or disappoint in 2025.

The 20 newcomers to be drawn in
The fans are happy about newbies, but which ones are really worth taking up fantasy designs this summer? Matt Bowen has a list.

16 players to act or act against or in dynasty
Knowing when you stay and when you have to go away from the players is of crucial importance for the success of the Dynasty League. Eric Moody is here to help.

To upgrade of players, downgrading due to the schedule of 2025
Mike Clay describes the teams and players with the simplest and hardest schedules in fantasy terms.

Strategy/game paths

The game book, part 2: Tips for non -traditional formats of Fantasy Football design for non -traditional formats
Mike Clay discusses his approach of design in various intensive league structures that attract less attention.

The game book: Plan a winning strategy for fantasy football design days
Mike Clay is in position and explains a successful approach to fantasy football designs from 2025.

A guide for Fantasy Football beginners to the salary limit designs
Eric Karabells offers an introduction to the advantages and disadvantages of salary degrees for fantasy football.

Why this is the season to try an IDP League
Tristan H. Cockcroft explains why the elaboration of defensive players increases the fun you can play imagination.

What is a superflex league and why should you try?
Tristan H. Cockcroft explains why starting two QBS instead of one maximizes fun and also changes the way they design.

10 ways to enjoy your league more
Daniel Dopp offers individual options to improve the enjoyment of fantasy football for you and your Leagusimates.

Single player analysis

Drake Maye A Top 10-QB in 2025?
Eric Moody explains why Maye is able to take the next step in the second year.

Should you take on Ashton Jeaty in fantasy designs via Saquon Barkley?
Liz Loza and Tyler Fulghum debate whether the hot rookie or the back of 2,000 yards are the better choice.

Travis Hunter's experience: How to maximize your fantasy potential
Would you like to play in a league where you get points for all contributions from Travis Hunter? That's how you do it.

Injuries

Working out of injury: McCafrey, Godwin and Olave to monitor among the players
Stephania Bell describes the players who recover from injuries and their prospects for this season.

Different

New functions in the ESPN Fantasy app: easier navigation, improved personalization
A list of the latest elements that have been added to the Fantasy app that you can enjoy this season.

Name of Fantasy football team names: How to select a winner
If you are inspired to name your fantasy team, Liz Loza offers a blueprint.

The fantasy team name generator
Answer a short quiz and will be rewarded with a suggestion for a team name that fits your style and personality.

Categories
Health

Doximity acquires Ai Startup Pathway Medical for 63 million US {dollars}

Doximity (Docs) Q3 income 2025

Doximity on the New York stock exchange for the first public offer on June 24, 2021.

Source: NYSE

Doximity Immerse yourself in artificial intelligence and announces the takeover of Startup Pathway Medical for 63 million US dollars on Thursday.

Pathway has created a AI-driven clinical reference instrument with which doctors can ask questions about guidelines, medication and studies. Pathway's answers are synthesized from medical literature, and Doximity said that the startup based in Montreal has one of the largest structured data records in medicine.

The platform of doximity, which has been referred to for doctors for years, helps the clinicians to stay up to date in medical news, find paperwork, find transfers and to carry out telEAALT appointments with patients. By acquiring paths, Doximity hopes that doctors will also contact the platform to answer their clinical questions.

“We hunted up and low, and I think we found the best company in the room to answer the questions of doctors with AI, and it was not in Silicon Valley,” said Jeff Tangney, co -founder and CEO of doximity, to CNBC in an interview.

The deal ended at the end of July due to a cash view of 26 million US dollars and up to 37 million US dollars in additional equity grants, said Doximity.

According to Tangney, the integration of doximity is in full swing, and companies are testing a combined product with thousands of doctors.

In the meantime, patients regularly turn to AI tools and chatbots to get answers to health-related questions.

While a live stream on Thursday, in which Openai announced his new model GPT-5, CEO Sam Altman said that health questions were one of the largest categories of chatt use, a contribution to X and added that the new model in this area was “much better”.

Doximity already has a free AI product, doximity GPT, with which doctors can generate insurance letters and summarize patient diagrams and reports. Pathway will bring additional “robustness” to the data that Doximity has in the back, said Dr. Amit Phull, Chief Clinical Experience Officer from Doximity.

“What Pathway brings this party or this marriage is that you have a very, very robust back-end data set that connects doses of guidelines for literature to quotes,” Phull told CNBC in an interview.

The Pathway model achieved 96% in the US Medical Licining Examination Benchmark, said Doximity, which doctors have to prove that they can understand and use medical knowledge.

In doximity, which went to the stock exchange in 2021, 10% rose by 10% this year after it rose by 90% in 2024. The company has a market capitalization of around 11 billion US dollars.

The stocks of doximity rose by about 6% on Thursday, after the company had reported results in the first quarter, the estimates exceeded the estimates. Sales rose by 15% to $ 145.9 million compared to the previous year, while analysts expected sales of USD 139.5 million according to LSEG. The result per share of 36 cents exceeded the 30-cent average estimation.

Categories
Entertainment

Malcolm-Jamal Warner's mom speaks after early loss of life

Malcolm-Jamal Warner's Mother, Pamela, Breaks Her Silence On The Actor's Untimely Passing (PHOTO)

The world still mourns the sudden loss of a loved one, and now, almost three weeks after his death, the person who knew it best speaks. With grace and strength, Pamela Warner– Mother of the actor Malcolm-Jamal Warner– opened publicly for the first time. But instead of concentrating on grief, she channel her love to honor her son's legacy in a powerful way.

Relatives: Doctor Who supposedly tried to save Malcolm-Jamal Warner when officials clarify details with daughter

Malcolm-Jamal Warner's mother breaks her silence

On August 6th, Pamela Warner started an Instagram page entitled: Malcolm-Jamal Warner Living Legacy to celebrate life and memory of her son. In the first post of the account, Pamela lovingly wrote: “This is the official report on Malcolm-Jamal Warner, who is lovingly led by his mother Pamela Warner.“She further promised that there would be further updates in the coming weeks, including initiatives and homes that are dedicated to the memory of the deceased actor. People Magazine reports that a formal tribute event is in the works and may take place later this year or early 2026.

Malcolms reflects his legacy in the middle of his death

In a warm Instagram carousel, Pamela Warner shared a written tribute to Malcolm's life and opened the deep love she had for him, and the profound influence he had on the people around him. The emotional message reflected on his legacy, his role as father and the light that he brought to everyone who knew him.

Pamela revealed in the Instagram post:

“He was a friendly, loving man with a huge heart for humanity. He wanted everyone to be aware of their inner strength and that they could be successful, achieved and transformed,” she wrote. “This was his latest mission and work, transformation, so that they are completely present in their lives.”

A background about Malcolm-Jamal Warner's death

Malcolm-Jamal Warner tragically died in Costa Rica after drowning while surfing the body during a family trip. According to the judicial examination authority, death was decided as an accident due to suffocation by immersion. Warner had played on the bank with his daughter before entering the water with a friend, where both were swept away by a strong current. While the friend certainly managed, Warner did not survive despite the efforts of bystanders and emergency crews. Malcolm's legacy is known for his iconic role as Theo Huxtable in 'The Cosby Show' and lives through his unforgettable achievements and the many lives he touched – on the screen and from.

Relatives: Malcolm-Jamal Warner was reportedly sponge with his young daughter when he drowned

What do you think with co -apartments?

Categories
Technology

The way to play like an expert – classes from an insider “Hai -Panzer”

How to present a complex product in 3 minutes – and win

They have spent a lifelong structure of skills, learned lessons, promotes relationships and developed a perspective that is as forward -looking and powerful as their personal drive. You have poured everything into your business. Now they have five minutes (or less) to communicate an irresistible vision for the world and to convince a group of viewed – and sometimes disrespectful – judges that they can make the vision real and make some money. How you do that?

A pitch competition is a unique moment: I set myself up, judged and organized in Miami to Mongolia. I am an entrepreneur and investor and I spent a decade to fight for “Shark Tank” and other business television shows. Every year I meet thousands of entrepreneurs around the world, rated their companies and help them prepare for their big moment.

I organized the Pitch battle at the TNW conference in June. The competition – won by Dutch startup Tap Electric has highlighted the history of a founder. Regardless of whether you throw the sharks at a tech conference or rock the stage, you will find some key elements here that make a pitch successful:

Annoy

Yes, nerves. While many people devote time and money to overcome and outperformance nerves, I think that nerves are a critical element for a successful pitch. Why? Nerves mean that they are interested. Some people are afraid to speak publicly, others have met from the moment and what could mean financing or exposure to their business, and nobody wants to submit a service that does not submit resonance. These are all reasons to take care of the field. These are all reasons to feel something – before, during and after.

Entrepreneurs who open up to the promise, intensity and the excitement of the moment create the possibility that these feelings will encourage a passionate pitch. The feeling of feeling the moment without being consumed from the moment is a key element for a successful pitch.

TNW City Coworking Space – where your best work happens

A area of work for growth, cooperation and endless networking opportunities in the heart of technology.

Research

A successful pitch begins long before you step on the stage. Do you know your audience and your judges. Find out who will be in the room, what it is important to you and how you are rated. In practice, this means researching the background and motivations of the judges. A Angel investor can prioritize the traction or the business model, while a company sponsor may pay attention to strategic orientation. Other judges can address companies that can “do” with the funds provided or resources.

Don't try to record everyone at once. Go to the group that is most important for this competition and give them confidence in your understanding of the market, your motivations and how you can progress.

Regardless of the phase in which your business is in your company, tell your history and clearly articulate how to use the available resources and/or be asked to achieve KPIs that use the judges and the overall competition.

First paint a living picture of the pain point. Then explain how your product or service appeals to this problem in a new way and highlights every unique technology or a unique approach. Next, emphasize examples of real world or user stories to make it accessible.

Finally, define the market chance across the entire addressable market (TAM). Yes, decision -makers want to know that their company has the market potential to grow and scale. In addition, the judges want to know how to use the available resources to reach and convert the market.

What do the resources that are available to the winner of the competition mean in relation to customer touchpoints? What do the points of contact in relation to conversions mean? What do the conversions mean in terms of top line revenue? And what does this turnover mean for the way to profitability?

audience

Connect with the audience. Let yourself be fueled by your energy. Invite them to take part. If you establish a real connection with your audience, you can distinguish yourself. Bring energy and enthusiasm to the stage. Smile, make eye contact and move with purpose. These simple actions make a formal pitch into an appealing conversation.

Invite the audience to get in touch early and often with you and your business. Ask a question, weave up in a call and reaction, set a hands exhibition, share left-hand-all these parts can drive the commitment beyond the pitch.

Instead of memorizing your pitch to memorize you to be ready for the unexpected. Bad luck, as if they are telling a friend an exciting story instead of reading foils. This real connection and eye contact, enthusiasm and a two-way feeling vibrate your message.

Questions

They would be surprised at how many entrepreneurs start their business without having a clearly defined question. As a business owner, you should ask about every audience that you imagine. It is up to you to know which resources are needed to bring your company to the next stage and ask about these resources.

Do not leave the most important part as a surprise – always indicate a clear, specific question. Your questions are central to the Pitch and it Tell the judges exactly what they need and why.

If the competition has defined price amounts or other resources, enter these resources in the ASK. Let the judges and the audience know that you have thought about how you can build your business in a practical way with this competition.

If, as is so often the case, your company needs additional means or resources that go beyond the available people during the competition, mention this broader one. Explain how the resources from the competition support their persecution of these resources.

Contents

A good pitch is not a single moment. Documenting the preparation, pitch and the results can be an incredible way to connect with your audience. By creating clips and other content from your field, you can set your business to the stage long after stopping the microphone.

Treat the entire process as valuable content. Document everything: your application, your acceptance in the competition (a service on and for yourself), preparatory work, exercise sessions, final foils and even your nerves!

Write down your exercise height on video whenever possible so that you can refine your delivery and later reuse clips. Save your pitch deck, photos and videos after the event. These materials become marketing gold. Take the polished two- to three-set “Elevator Pitch” and use it in e-mail newsletters, on your website or in social media posts.

Write a short blog or a LinkedIn contribution about your Pitch experience -what you have learned, the result and all other knowledge you have gained. Keep your community up to date: This visibility can attract customers, partners and even future investors. Use social media and other channels to strengthen your history.

A winner is based on preparation, clarity and connection. Explore your judges, tell a crispy story, get involved with your audience, specifically stand up for the resources and the strategy, ask a confident and relevant question and then make them a presentation in many convincing content.

These elements work together to make their pitch unforgettable and effective. A pitch, including them, can charge a company and accelerate its way to growth.

Categories
Science

Other than the newly performing AI calculus facilities, pure gasoline will rely – that’s that with that?

Apart from the newly performing AI calculus centers, natural gas will rely - that is that with that?

By Gary Abernathy

This article was originally published in the Empowerment Alliance and is published here again with permission.

In an age of infinite propaganda and spin, there are still rare times when undeniable evidence does not leave any room for arguments. This is the case with the aspiring data centers for artificial intelligence and energy that is necessary for preservation and expansion.

The developing AI technologies and their quick implementation in almost any area of life can be intimidating and even scary. The technology seems to be at risk of surpassing the controls and parameters that are necessary to use the amazing possibilities of AI. The Stanley Kubrick classic from 1968, “2001: A Space Odyssey”, warned of a future in which “thinking” computers would refuse to obey the orders of their human creators.

While ethics discuss with the philosophical questions about AI and politicians to discuss the laws, the United States not only have to compete with other nations, but also ensure that it remains the worldwide leader. For this purpose, AI centers continue across the country and sets up the requirements for electrical networks, unlike something that was previously seen.

The Institute for Energy and Environment of Penn State recently reported that the data centers consumed 4.4% of electricity in the USA in 2023 alone. This is an impressive number. However, the institute assumed that by 2030-2035 data centers “20% of the global power consumption could make up and the power grids are immensely burdened”.

The Energy Initiative of MIT INFORMATION IN THE THE THE CIT Technology. Most people did not make a second superior to her because they use their services every day through companies such as Google, Meta, Microsoft and Amazon.

“Without realizing it, consumers rely on AI when they stream a video, carry out online banking or carry out an online search,” remarked. “Behind these functions, more than 10,000 data centers worldwide, each with a huge warehouse with thousands of computer servers and other infrastructures for storing, managing and processing data. There are now over 5,000 data centers in the USA and are built up every day, both in the USA and worldwide.”

Universities like Penn State and with are concerned about the “environmental footprint” of the data centers. Many who have predicted that “alternatives” would one day supply the world with electricity increasingly recognize the fact that refueling the data center boom requires traditional energy sources, in particular natural gas.

“While renewable energies such as wind and solar become an important role in the energy -future games, they alone cannot be operated around the Ai infrastructure clock,” said Forbes recently. “That is why natural gas and nuclear are restored in lattice planning. Several supply companies have rapidly persecuted suggestions for new natural gas peaker systems. Others rate small modular core reactors as potential solutions for the provision of constant, low-carbon basela performance.”

While some data center developers may consider building small nuclear reactors, natural gas has the upper hand because it is easily available and can be used faster – and it is increasingly being considered “green” energy, also by legislative Fiat.

It is important to withdraw and remember the contradictory courses that were displayed less than a year ago by the US government on the one hand and the AI boom on the other. While the United States urgently needed to keep up with other nations, especially in China, with the construction of AI data centers, the bidet management implemented guidelines for the elimination of energy on a fuel basis in favor of taxpayer-subsidized solar and wind farms.

Essentially, the United States was on the right track to lower at the same time than new technologies larger and more reliable power sources than ever demanded. Thank God the voters came to rescue in 2024. President Trump and his administration work overtime to undo the damage to the previous administration. Trump's energy department, led by two executive regulations – “Remove obstacles for American leadership in artificial intelligence” and “unleash American energy” – examines ways to facilitate and accelerate the AI infrastructure.

On July 15, the Trump administration announced more than 90 billion US dollars of AI and energy investments in Pennsylvania, including 25 billion US dollars in calculation centers and infrastructure, the investment of Blackstone in 25 billion US dollars in data centers and natural gas plants as well as an investment of $ 6 billion in The expandation of 6 billion US dollars. “

Last week Trump kept the keynote address at a half-day summit in Washington DC, which was organized by the all-in-podcast and the Hill & Valley Forum entitled “Winning of the AI race”. In the event, other administrative officers and leaders of the AI Tech world were also presented.

The proactive attitude of the Trump government compared to AI and the associated data centers should be welcomed by all Americans. Likewise, people throughout the political spectrum should have clear eyes over the emerging demands on the electrical network of our nation and the fact that “renewable energies” such as wind and solar are simply not the task. No political propaganda or spin will change this unchangeable scientific reality.

Natural gas is the future and the future is now. If you are not sure of this, Google just google it – which is possible thanks to an electrical network, which is mainly driven by reliable, affordable and available natural gas.

Gary Abernathy is a long -time newspaper editor, reporter and columnist. He was a columnist for Washington Post from 2017-2023 and a frequent guest analyst on numerous media platforms. It is a columnist for the Empowerment Alliance, which deals with realistic approaches to energy consumption and environmental protection. The “Tea Takes” column of Abernathy is published every Wednesday and delivered to your inbox!

This article was originally published by Realclearergy and provided via Realclearwire.

Like this:

How Load…

Do you discover more from watts?

Subscribe to the latest posts to your e -mail.